Show simple item record

dc.contributor.authorYao, TT, et al. Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing
dc.date.accessioned2020-03-20T18:48:07Z
dc.date.available2020-03-20T18:48:07Z
dc.date.issued2020-02-27
dc.identifier.urihttps://doi.org/10.1002/jmv.25729en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/499
dc.description.abstractIn the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19.en_US
dc.titleA Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS coronavirus-A Possible Reference for Coronavirus disease-19 Treatment Optionen_US
eihealth.countryChinaen_US
eihealth.categoryCandidate therapeutics RDen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySave Lives / Salvar Vidasen_US
dc.relation.ispartofjournalJournal of Medican Virology


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record